- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
Dear Duchenne Community, As we come together for the annual Parent Project Muscular Dystrophy (PPMD) conference over the next several days, we want to begin by recognizing the strength, resilience and partnership of this community. We are grateful for the opportunity to connect with so many families, advocates and clinicians and to continue advancing this ... Read more The post Letter to the Duchenne Community appeared first on Solid Biosciences.
Dear Duchenne Community, Today at the 2026 MDA Clinical & Scientific Conference, we announced a positive clinical update on the SGT-003 gene therapy program. This update includes interim safety and biomarker data from the ongoing Phase 1/2 INSPIRE DUCHENNE clinical trial. To date, 40 participants have been dosed with SGT-003. The data include robust expression ... Read more The post Letter to the Duchenne Community appeared first on Solid Biosciences.
Dear Duchenne Community, As we begin the new year, we want to wish you and your families a happy and healthy 2026 and to thank you for your continued partnership. We are writing to share an update on SGT-003, our investigational next-generation gene therapy for Duchenne muscular dystrophy. Today, we announced that 33 participants have ... Read more The post Letter to the Duchenne Community appeared first on Solid Biosciences.
Dear Friedreich’s ataxia (FA) community, As we begin the new year, we want to wish you and your families a happy and healthy 2026 and thank the FA community for your trust and partnership. We are writing to share an important update on FALCON, our first-in-human clinical study evaluating SGT-212, Solid’s investigational gene therapy for Friedreich’s ataxia. Today, Solid Biosciences announced the first participant has been dosed in FALCON, a Phase 1b, open-label, dose-finding clinical trial ... Read more The post Letter to the FA Community appeared first on Solid Biosciences.
Dear Duchenne Community, We are pleased to share a meaningful update on the INSPIRE DUCHENNE clinical study, our multi-center, open-label clinical trial evaluating SGT-003, our investigational gene therapy for the treatment of Duchenne muscular dystrophy. As of August 12, 2025, 15 patients living with Duchenne have received SGT-003 in this study. The trial now includes ... Read more The post Letter to the Duchenne Community appeared first on Solid Biosciences.
Dear CPVT Community, We are pleased to introduce Solid Biosciences to the CPVT community—and to share important news about our investigational gene therapy, SGT-501. Patient-focused and founded by individuals directly impacted by Duchenne muscular dystrophy, Solid’s mission is to improve the daily lives of people living with rare neuromuscular and cardiac conditions. What began as ... Read more The post Letter to the CPVT Community appeared first on Solid Biosciences.
Letter to the Duchenne Community: With heartfelt gratitude, I want to begin by thanking the patients and families participating in the INSPIRE DUCHENNE clinical study – you are the true heroes of this journey. Your bravery and commitment are what drive our work as we strive to advance a more effective and safe gene therapy ... Read more The post Letter to the Duchenne Community – INSPIRE DUCHENNE Positive Initial Clinical Trial Data appeared first on Solid Biosciences.
Dear Friedreich’s Ataxia Community, We are excited to officially introduce Solid Biosciences to the FA community. Solid Biosciences was founded by individuals directly impacted by Duchenne muscular dystrophy, driven by a deeply personal mission to develop meaningful therapies for patients and families. Since that time, our mission has expanded to include other urgent, rare neuromuscular ... Read more The post Letter to the FA Community appeared first on Solid Biosciences.
Dear Duchenne Community, Earlier today we reported third quarter financial results and provided updates on Solid Biociences Inc.’ (“Solid”) business. Among the highlights, we shared new information about INSPIRE DUCHENNE, our clinical trial of our next-generation AAV gene therapy candidate, SGT-003, for the treatment of patients living with Duchenne. INSPIRE DUCHENNE: Status update INSPIRE DUCHENNE ... Read more The post Letter to the Duchenne Community – INSPIRE DUCHENNE update & expansion appeared first on Solid Biosciences.
Dear Duchenne Community, We are writing to share an important update on INSPIRE DUCHENNE, our Phase 1/2 clinical trial of SGT-003 for the treatment of patients living with Duchenne. At Solid Biosciences, our mission is driven by the needs and hopes of the Duchenne community, and we are grateful for the trust and partnership you have ... Read more The post Letter to the Duchenne Community – INSPIRE DUCHENNE update appeared first on Solid Biosciences.
